Voya Investment Management LLC Increases Stock Holdings in Glaukos Co. (NYSE:GKOS)

Voya Investment Management LLC boosted its stake in Glaukos Co. (NYSE:GKOS - Free Report) by 266.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 200,698 shares of the medical instruments supplier's stock after purchasing an additional 145,890 shares during the quarter. Voya Investment Management LLC owned about 0.36% of Glaukos worth $30,093,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of GKOS. Stifel Financial Corp grew its holdings in Glaukos by 37.7% in the third quarter. Stifel Financial Corp now owns 4,230 shares of the medical instruments supplier's stock worth $551,000 after purchasing an additional 1,157 shares during the period. Barclays PLC grew its holdings in shares of Glaukos by 394.4% during the third quarter. Barclays PLC now owns 89,699 shares of the medical instruments supplier's stock valued at $11,686,000 after buying an additional 71,556 shares during the last quarter. Sanctuary Advisors LLC acquired a new position in shares of Glaukos during the third quarter valued at about $258,000. Tidal Investments LLC grew its holdings in shares of Glaukos by 83.1% during the third quarter. Tidal Investments LLC now owns 14,908 shares of the medical instruments supplier's stock valued at $1,942,000 after buying an additional 6,767 shares during the last quarter. Finally, Franklin Resources Inc. grew its holdings in shares of Glaukos by 80.1% during the third quarter. Franklin Resources Inc. now owns 15,621 shares of the medical instruments supplier's stock valued at $2,031,000 after buying an additional 6,948 shares during the last quarter. 99.04% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Glaukos

In other news, insider Tomas Navratil sold 3,416 shares of Glaukos stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $147.14, for a total value of $502,630.24. Following the transaction, the insider now owns 72,437 shares in the company, valued at approximately $10,658,380.18. The trade was a 4.50 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Alex R. Thurman sold 1,520 shares of Glaukos stock in a transaction dated Tuesday, March 25th. The stock was sold at an average price of $106.84, for a total value of $162,396.80. Following the completion of the transaction, the chief financial officer now owns 53,431 shares in the company, valued at approximately $5,708,568.04. This represents a 2.77 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 6.40% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on GKOS shares. Piper Sandler reduced their price objective on shares of Glaukos from $180.00 to $165.00 and set an "overweight" rating for the company in a report on Tuesday, April 15th. Truist Financial restated a "buy" rating and issued a $135.00 target price (down previously from $140.00) on shares of Glaukos in a research note on Thursday. Wells Fargo & Company lowered Glaukos from an "overweight" rating to an "equal weight" rating and reduced their target price for the company from $160.00 to $86.00 in a report on Thursday. Mizuho reduced their target price on Glaukos from $200.00 to $175.00 and set an "outperform" rating for the company in a report on Wednesday, April 16th. Finally, Stifel Nicolaus reduced their target price on Glaukos from $140.00 to $115.00 and set a "buy" rating for the company in a report on Thursday. One analyst has rated the stock with a sell rating, two have issued a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $139.50.

Glaukos Price Performance

NYSE GKOS traded down $15.62 during trading hours on Thursday, reaching $78.63. 2,063,351 shares of the stock traded hands, compared to its average volume of 658,180. The stock has a 50 day simple moving average of $99.10 and a two-hundred day simple moving average of $129.41. Glaukos Co. has a 1 year low of $77.56 and a 1 year high of $163.71. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.54 and a quick ratio of 4.71. The company has a market cap of $4.49 billion, a price-to-earnings ratio of -27.43 and a beta of 0.88.

Glaukos (NYSE:GKOS - Get Free Report) last released its quarterly earnings results on Wednesday, April 30th. The medical instruments supplier reported ($0.22) earnings per share for the quarter, beating analysts' consensus estimates of ($0.33) by $0.11. Glaukos had a negative return on equity of 16.53% and a negative net margin of 39.04%. The business had revenue of $106.66 million for the quarter, compared to the consensus estimate of $102.78 million. During the same quarter last year, the business posted ($0.70) earnings per share. The company's revenue for the quarter was up 24.6% on a year-over-year basis. On average, analysts predict that Glaukos Co. will post -1.08 EPS for the current fiscal year.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.